Our brand new study published today in Cancer Discovery.
Now in @CD_AACR: #Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid #Leukemia – @glytsou @xufeng_chen Emmanouil Zacharioudakis @ProfGavathiotis @iannisaifantis1 et al. @RutgersCancer @ae_cancercenter @EinsteinMed @Perlmutter_CC @NYUGSOM_Path https://t.co/Ehq9QtqAMy pic.twitter.com/hbZmpNh7UE
— Elizabeth McKenna (@ElizSMcKenna) April 24, 2023
We asked, “Which are the common mechanisms of resistance to various BH3-mimetics-based therapies that are used in clinics or under clinical investigation in AML?”. Applying CRISPR/Cas9 screens and establishing preclinical drug-resistant AML models, we showed that mitophagy promotes resistance to BH3-mimetic drugs in AML. Targeting key regulators of mitochondrial clearance can reverse drug resistance.
Check out our brand new study @CD_AACR. We asked, “Which are the common mechanisms of resistance to various BH3-mimetics-based therapies that are used in clinics or under clinical investigation in Acute Myeloid Leukemia?” https://t.co/hvT9fnkm2d
— Christina Glytsou (@glytsou) April 24, 2023